Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Limitations of CAR-T manufacture in the UK

Despite recent approvals in CAR-T therapy, there are still limitations of CAR-T manufacture and access in the UK. Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses some of the challenges associated with CAR-T administration and manufacture in the UK, and the hope for ciltacabtagene autoleucel (cilta-cel) to receive NICE approval and provide patients with relapsed/refractory (R/R) disease with more options. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.